1,721,062 research outputs found

    ACE-INIBITORI NELLA TERAPIA DELL’INSUFFICIENZA CARDIACA CONGESTIZIA NEL CANE: EFFETTI COLLATERALI A MEDIO E LUNGO

    No full text
    Nella terapia dell'insufficienza cardiaca congestizia del cane abbiamo utilizzato, per periodi compresi tra 1 e 17 mesi, farmaci inibitori dell'enzima di conversione dell'Angiotensina (ACE-inibitori), capaci di indurre miglioramenti emodinamici dimostrabili sul piano clinico diretto e strumentale. Tuttavia, in 5 soggetti dei 16 trattati con Enalapril (Enapren "R") o Lisinopril (Zestril "R") alla dose di 0,2 - 0,5 mg/kg/die, abbiamo osservato, a distanza variabile dall'inizio della terapia, la comparsa, in associazione diversa, di insufficienza renale, di arrossamento, grattamento ed ulcere a livello cutaneo, di tosse continua, stizzosa e non produttiva, nonchè di polidipsia. Tali disturbi sono stati interpretati come effetti collaterali legati al tipo di molecola somministrata, poichè sono regrediti con l'interruzione della somministrazione del farmaco o con la sua sostituzione con altro ACE-inibitore. Sulla base delle nostre osservazioni, pur se riferite ad un campione esiguo di soggetti, è ipotizzabile che gli effetti descritti siano più frequenti di quanto noto dalla letteratura e che possano costituire una limitazione alla terapia protratta con ACE-inibitori. In the therapy of congestive heart failure in dogs inhibitors of the angiotensin converting enzyme was used for variable time from 1 to 17 months due to their ability of inducing haemodynamic improvement demonstrable on a direct and instrumental clinical level. However in 5 of the 16 subjects treated with Enalapril (Enapren "R") or Lisinopril (Zestril "R") at the dose between 0,2 and 0,5 mg/kg/die, at varying time intervals from the beginning of the therapy the appearance in of the following in different combinations were observed: renal failure, cutaneus rashes, scratching and skin ulcers, chronic dry irritative cough, as well as polydipsia. These disorders were interpreted as collateral effects linked with the type of molecule administred since they regressed when the administration of the drug was interrupted or when it was substituted with another ACE-inhibitor. On the basis of these observations, even if they refer to an exiguous sample of subjects, it can be hypothesized that the effects described are more frequent than that is referred by literature and they can constitute a limitation for chronic therapy with ACE-inhibitors

    Left-sided congestive heart failure in a dog with intraventricular rhabdomyosarcoma

    No full text
    CASE REPORT A 9-year-old female Labrador Retriever was referred for evaluation of a 7-day history of exercise intolerance and dyspnoea. Thoracic radiographs showed moderate left atrial enlargement and severe pulmonary oedema. Transthoracic echocardiography revealed a heterogeneous hyperechoic mass extending from the left inflow tract to the outflow tract and protruding through the aortic ostium during systole. Spectral Doppler echocardiography was consistent with left ventricular inflow and outflow tract obstruction secondary to the mass. Because of the lack of response to treatment and the poor prognosis, the dog was euthanased and necropsy was performed. A large intracavitary mass, originating from the left ventricular free wall, filled the ventricular cavity. Mitral leaflets were distorted and thickened with shortened chordae. Microscopic findings were consistent with a rhabdomyosarcoma. CONCLUSION This report describes an intracavitary left ventricular rhabdomyosarcoma in a dog, causing left ventricle outflow tract obstruction and functional mitral stenosis that was clinically associated with pulmonary oedema
    corecore